Turn this list into pipeline.
Biotech Companies in London: 700+ Active Firms (2026)
Biotech companies in London develop biological research, therapeutics and platform technologies within the UK life-sciences framework.
Buying centres in London biotech cluster around therapeutic research, diagnostics and discovery tools, plus platform technologies that support translational science. Buyers tend to be pharmaceutical groups, clinical research teams, academic-linked labs, public-sector research bodies and investors assessing IP-led businesses. Engagements range from specialist research-services work to enterprise co-development, licensing and clinical-readiness programmes, with sales cycles shaped by evidence quality, regulatory pathway and the maturity of the asset. The relevant operating profile is usually a lean scientific team with defensible intellectual property, venture or grant funding, and a route from laboratory validation towards regulated development or commercial partnerships.
Read more
London has 721 actively trading biotech companies in this list, and their reported employment footprint stands at 1,587 people. The cohort is weighted towards younger and smaller businesses: 230 were incorporated since 2022, while 33 have reported turnover above £5M. That split fits the capital-intensive nature of life sciences in the capital, where many firms remain research-led for long periods before reaching repeatable commercial revenue. For researchers and buyers, the practical distinction is between early translational companies, revenue-generating tools and diagnostics suppliers, and the smaller group already operating at a scale where procurement, compliance and partnership processes become more formal.
UK biotech and biopharmaceutical work runs through activity-specific rules rather than a single sector licence. Clinical research requires Good Clinical Practice, ethics review and informed consent, while the MHRA approves clinical trial applications, assesses marketing authorisations and oversees pharmacovigilance after approval. Market access can add a separate evidence step, with health technology assessment bodies reviewing cost effectiveness before routine public reimbursement. Sector representation sits with research-based pharmaceutical and biotech trade bodies, which matters because therapeutics, diagnostics, platform and discovery-tool businesses face different evidential burdens even when they share investors, laboratories and scientific talent.
The London pipeline appears skewed towards early-commercial and translational businesses rather than mature revenue-scale operators. Venture-financed discovery platforms and specialist therapeutics developers tend to face a longer route from laboratory validation to repeatable revenue than software or services peers, so buyer due diligence is likely to keep focusing on IP position, clinical evidence, regulatory readiness and partnership quality. Scale-up scarcity may also keep acquisition interest directed at platforms that can support multiple programmes, while diagnostics and tools businesses may move earlier towards commercial partnerships. Regulatory pressure is unlikely to ease, but it gives credible operators a clearer way to differentiate from research-only ventures.
721
Active firms
2026
33
Above £5M
reported revenue
230
Since 2022
new incorporations
Key facts
About 4% of the trading cohort reports turnover above £5M (33 of 721 firms) — the rest sits below that revenue band.
31% of the cohort was incorporated since 2022 (230 firms), so a sizeable share is in its first few filing cycles.
The MHRA approves clinical trial applications, assesses marketing authorisations and monitors post-authorisation safety through pharmacovigilance.
Approved medicines may also be reviewed by health technology assessment bodies such as NICE before routine NHS use.
The UK life-sciences industry generated £146.9 billion in turnover in 2023/2024, with biopharmaceuticals accounting for 67% of the total.
BIA reported £3.5 billion of UK biotech equity investment in 2024, a 94% increase on the previous year and the highest annual figure since £4.5 billion in 2021.
The UK accounted for 11.5% of global medical-sciences citations in 2023, behind only the USA and China.
Top London biotech companies
LABGENIUS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops therapeutic antibodies using a machine learning‑driven discovery platform integrating automation, synthetic biology and high‑throughput experimentation. Conducts antibody discovery and…
Serves biopharmaceutical companies and development partners in oncology, particularly organisations working on complex or multispecific antibody therapeutics for solid tumours.
Financial Health
HealthyHealthy · Hiring · 13% CAGR over 4y
Location
Wave Science Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops RNA-based therapeutics using proprietary chemistry and RNA-targeting technologies. Conducts research, clinical development and manufacturing of medicines for genetic and metabolic disorders,…
Serves patients and families affected by serious rare and common disorders, plus healthcare, biopharma collaboration and investor stakeholders focused on RNA therapeutics.
Financial Health
HealthyHealthy · 0% CAGR over 2y
Location
LIFT BIOSCIENCES LIMITED
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops neutrophil-based cell therapies for cancer treatment. Its platform produces immunomodulatory alpha neutrophils (IMANs), allogeneic cell therapies designed to kill tumour cells and stimulate…
Targets oncology healthcare markets, including patients with advanced solid tumours such as cervical and head and neck cancers, alongside biotech investors and clinical development partners.
Financial Health
StableStable · -50% CAGR over 4y
Location
Swarm Oncology Limited
Trajectory
2y · 2023–NowFinancial sub-scores
Computed from 2 filingsDevelops personalised T cell therapies for cancer treatment. Uses a platform combining in vivo priming and ex vivo optimisation to create targeted cell therapies designed to recognise…
Serves oncology healthcare and life sciences organisations, including hospitals, research collaborators and commercial partners, with engagement also aimed at specialist investors in T cell therapy.
Financial Health
WeakWeak · Hiring · 100% CAGR over 1y
Location
Develops microbial immunotherapy treatments using engineered Salmonella bacteria and synthetic biology. Its platform targets tumors and delivers therapeutic molecules to stimulate anti‑tumor immune…
Targets oncology healthcare markets, with programmes aimed at patients with non-muscle invasive bladder cancer and other difficult-to-treat cancers, plus biopharma stakeholders interested in cancer…
Location
Provides contract research services for pharmaceutical and biotechnology companies, including early‑phase and Phase II–III clinical trials, human challenge studies for infectious diseases, laboratory…
Serves pharmaceutical, biotech and vaccine developers, plus clinical trial sponsors working on infectious, respiratory, cardiometabolic, renal and hepatic disease programmes.
Location
Centauri Therapeutics Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops immunotherapy treatments for infectious diseases and oncology. Uses its proprietary Alphamer platform to create drug candidates that redirect naturally occurring antibodies to target…
Serves healthcare markets treating vulnerable patients with life-threatening infectious diseases and oncology indications, including clinical stakeholders focused on severe or drug-resistant…
Financial Health
StrongStrong · Hiring · 24% CAGR over 4y
Location
Conducts pharmaceutical research and development, including clinical research, to develop medicines and vaccines for human and animal diseases. Collaborates with healthcare providers, academic…
Serves healthcare providers, NHS organisations, patients and patient groups, academic and research partners, and animal health customers in the UK.
Location
NORTHWEST BIOTHERAPEUTICS CAPITAL LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops dendritic cell–based immunotherapies for cancer. Focuses on DCVax vaccine platforms, including DCVax‑L, DCVax‑Direct and DCVax‑Prostate, and conducts clinical trials targeting glioblastoma,…
Serves cancer patients and oncology healthcare organisations, especially those focused on glioblastoma and inoperable solid tumour cancers, with additional communications aimed at biotech investors…
Financial Health
DistressedDistressed
Location
NOVALGEN NEWCO LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops multi-specific antibody immunotherapies using a proprietary AutoRegulation platform. Conducts clinical-stage research and development of biologic drugs targeting cancer, autoimmune,…
Serves life sciences partners and patient communities, including people affected by oncology, autoimmune, haematological and metabolic disorders, patient organisations, clinical trial participants,…
Financial Health
StableStable
Location
JUVENESCENCE UK LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops medicines targeting biological mechanisms of ageing to prevent and treat age‑related diseases. Conducts clinical drug development using small molecules, biologics and cell therapies,…
Serves healthcare and biopharma stakeholders focused on age-related diseases, including clinical partners, potential pharmaceutical acquirers or licensees, investors, and ultimately patients needing…
Financial Health
StableStable · -12% CAGR over 4y
Location
Synx Therapeutics Ltd
Trajectory
1y · 2025–NowDevelops emactuzumab, a CSF‑1R monoclonal antibody, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage‑driven diseases. Conducts biopharmaceutical research and clinical…
Targets people living with tenosynovial giant cell tumours (TGCT) and other macrophage-mediated diseases, with a global focus on rare-disease treatment needs.
Financial Health
Insufficient historyInsufficient history
Location
DUKE STREET BIO LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops cancer therapeutics using precision medicine approaches. Research focuses on targeting DNA damage response (DDR) vulnerabilities in tumours and activating anti‑tumour immune responses, with…
Targets the oncology healthcare market, ultimately serving cancer patients with specific genetic alterations and the clinicians and health systems involved in cancer care.
Financial Health
StableStable · -67% CAGR over 4y
Location
SYNTHACE LIMITED AND ITS SUBSIDIARY
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops cloud-based software used by life sciences research teams to design, automate and analyse biological experiments. Platform supports assay development and multivariate experimental design and…
Serves B2B life sciences R&D organisations, especially drug discovery and discovery biology teams in pharma and biotech, including scientists working on assay development, media optimisation and…
Financial Health
WeakWeak · -70% CAGR over 4y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and commercializes biopharmaceutical therapies focused on neurological and psychiatric conditions. Conducts research, clinical development, and marketing of prescription medicines and drug…
Serves clinicians and healthcare organisations in neuroscience care, as well as patients, families and caregivers affected by neurological conditions.
Financial Health
HealthyHealthy
Location
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops drug and cell-based therapies targeting gastrointestinal diseases. Its pipeline includes a small‑molecule candidate aimed at preventing bowel cancer by inhibiting abnormal cell growth, and a…
Targets pharmaceutical partners, investors and clinical research stakeholders in gastrointestinal disease, with products aimed at patients with FAP, Crohn’s-related perianal fistulas, IBD and bowel…
Financial Health
DistressedDistressed · -24% CAGR over 4y
Location
Carrick Therapeutics
Develops small‑molecule cancer therapies. Conducts clinical research on inhibitors targeting CDK7 and CDK12/13 and evaluates drug combinations in clinical trials for breast, prostate, ovarian and…
Targets oncology healthcare markets, including pharma partners, clinicians, research institutions and hospitals treating patients with advanced breast, prostate, ovarian and other aggressive cancers.
Location
Synteny Biotechnology Limited
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops AI-driven computational platforms that analyse biological sequence, structure and physics data to model molecular recognition and design precision T‑cell receptor (TCR) bispecific therapies…
Serves biopharmaceutical companies and research organisations focused on immunology, oncology and biologic drug discovery, particularly teams seeking partners for precision TCR bispecific therapy…
Financial Health
WeakWeak · Hiring · 52% CAGR over 4y
Location
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsDevelops a consent-based health data platform that links patients’ electronic health records, genomic data, biomarkers and reported outcomes. Provides pharmaceutical sponsors with real‑world evidence…
Serves life sciences sponsors, including pharmaceutical and biotech teams seeking consented patient cohorts and real-world evidence; also engages patients, healthcare professionals and investors.
Financial Health
StableStable · -13% CAGR over 3y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops computational and machine learning software for oncology, analysing molecular and clinical data to predict patient response to cancer therapies. Provides a platform for visualising datasets,…
Serves biopharma and oncology research teams, plus clinical research users developing cancer therapies. Targets partners using molecular and clinical data for therapeutic development, translational…
Financial Health
StrongStrong · Growing, Hiring · 37% CAGR over 4y
Location
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops drug delivery technologies and precision medicines using engineered polymer materials. Operates a clinical‑stage therapeutic pipeline focused on ophthalmology and central nervous system…
Serves pharmaceutical and biotech partners in ophthalmology, CNS, orphan diseases and pain therapies, with programmes ultimately aimed at patients needing improved drug delivery.
Financial Health
StableStable · Hiring · 6% CAGR over 2y
Location
CS Pharmaceuticals Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops and commercialises pharmaceutical products focused on ophthalmology and rare diseases. Licenses and advances drug candidates, including treatments for Meibomian gland dysfunction, and…
Serves pharmaceutical partners and healthcare markets in ophthalmology and rare diseases, with emphasis on China-West development and commercialisation pathways.
Financial Health
StableStable · 0% CAGR over 2y
Location
VIRAMAL LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops pharmaceutical therapies for women’s sexual and reproductive health, including treatments targeting conditions such as endometriosis, chronic pelvic pain, menopause and hormonal disorders,…
Targets women from reproductive age onwards, particularly patients with sexual and reproductive health needs such as endometriosis, chronic period pain, menopause, fertility and vaginal health issues.
Financial Health
StableStable · Hiring · 3% CAGR over 4y
Location
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsConducts biotechnology research and development focused on identifying and advancing therapeutic drug assets. Uses artificial intelligence, solid-form chemistry, and asset repositioning to develop…
Targets biopharmaceutical companies, strategic M&A partners and investors, rather than consumers, with licensing and partnership opportunities around therapeutic assets.
Financial Health
StableStable · Hiring · 140% CAGR over 2y
Location
BIO MOLECULAR SYSTEMS LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops and manufactures laboratory instruments and software for life science research and diagnostics, including real‑time PCR cyclers, automated liquid handling systems, and workflow software for…
Sells B2B to clinical diagnostics and life science research laboratories worldwide, including academic institutes, biotech and pharmaceutical teams running genomics, qPCR, NGS library prep and drug…
Financial Health
StrongStrong · Growing, Hiring · 19% CAGR over 4y
Location
SOLENO THERAPEUTICS UK LTD
Trajectory
4y · 2022–NowDevelops and commercialises pharmaceutical therapies for rare genetic and complex diseases. Conducts research, clinical development, and regulatory activities to advance drug candidates and bring…
Serves patients and families affected by complex, life-threatening rare genetic disorders, alongside healthcare stakeholders involved in rare disease treatment and access.
Financial Health
Insufficient historyInsufficient history
Location
Macarthys Laboratories
Conducts biopharmaceutical research and development focused on cancer and infectious diseases. Develops experimental therapies, runs clinical trials, and manufactures biologic medicines, while…
Serves patients with severe illnesses, especially cancer, infectious diseases and chronic disorders, alongside healthcare partners, researchers and organisations involved in clinical trials and…
Location
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops biotechnology for discovering and cultivating previously unculturable microbes using genomics, machine learning and bioengineering to identify novel microbial metabolites and chemistries,…
Serves primarily B2B organisations in healthcare and agriculture seeking novel antimicrobial chemistries, including developers of antimicrobials, plant protectants, gene therapies and cleaner…
Financial Health
StableStable · -64% CAGR over 4y
Location
HAMMERSMITH MEDICINES RESEARCH LIMITED
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsProvides clinical research services for pharmaceutical and biotechnology companies, specialising in Phase 1 and early Phase 2 trials. Offers study design, regulatory support, volunteer recruitment,…
Serves pharmaceutical and biotechnology companies worldwide, including drug developers of all sizes needing outsourced early-stage clinical trial support.
Financial Health
StableStable · 0% CAGR over 2y
Location
Develops and commercialises vaccines and diagnostic products, including tuberculosis skin tests, and supports vaccine manufacturing and supply initiatives. Engages in regulatory approvals, research…
Serves public health agencies, governments, healthcare systems and global health organisations procuring vaccines and diagnostics, as well as pharmaceutical partners in the UK, Europe, Africa and…
Location
Micrographia Bio Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsConducts life sciences research developing AI‑driven spatial proteomics and microscopy technologies to visualise protein interactions inside cells, supporting drug discovery and the development of…
Financial Health
StrongStrong · Growing, Hiring · 28% CAGR over 4y
Location
COHORT SCIENCE LIMITED
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsDevelops a research platform that builds consented patient cohorts through healthcare partners, enabling life science companies and researchers to recruit participants and access electronic health…
Serves life science companies and researchers, plus healthcare institutions and professionals, seeking patient cohorts and real-world evidence for clinical research. Also engages patients and…
Financial Health
HealthyHealthy
Location
CURA TECH THERAPY LIMITED
Trajectory
1y · 2025–NowDevelops multimodal immunotherapies for cancer and age‑associated diseases. Uses recombinant fusion proteins, including lead candidate CT101, designed to activate immune responses, reduce tumour…
Targets pharmaceutical and biotechnology companies as strategic partners, with end markets including patients with metastatic cancer, infections, fibrotic disease and senescence-related conditions.
Financial Health
Insufficient historyInsufficient history
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and provides laboratory diagnostic assays and analytical services that assess tumour chemosensitivity and immune response markers to guide selection of chemotherapy, targeted therapies, and…
Serves healthcare providers and clinical teams treating patients with cancer and autoimmune diseases, including oncology practices, hospitals and translational medicine researchers.
Financial Health
StrongStrong · Hiring · 11% CAGR over 4y
Location
PCR BIO SYSTEMS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies PCR and qPCR reagents for life science research and molecular diagnostics, including DNA polymerases, probe and dye master mixes, reverse transcriptase kits, nucleic acid…
Serves life science researchers, academic and commercial laboratories, molecular diagnostics developers, and NGS/qPCR users in research and diagnostic settings.
Financial Health
DistressedDistressed · -67% CAGR over 4y
Location
Sharptx Limited
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops small‑molecule drug therapies for hereditary diseases using automated laboratory experimentation and computational modelling platforms. Research programmes target genetic disorders including…
Targets patients with rare hereditary disorders, especially Gaucher disease, familial frontotemporal dementia and Niemann-Pick type C, along with healthcare providers and systems involved in genetic…
Financial Health
WeakWeak · -16% CAGR over 4y
Location
Helperby Therapeutics Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops combination therapies using existing antimicrobial drugs to treat antibiotic‑resistant bacterial infections. Conducts research and clinical development of synergistic antibiotic combinations…
Serves hospitals, clinicians and healthcare systems treating patients with resistant bacterial infections, with relevance to public and private healthcare providers and pharmaceutical partners…
Financial Health
DistressedDistressed · -65% CAGR over 4y
Location
Metabolon
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides metabolomics testing and analysis services for life sciences and biopharma research, including untargeted and targeted metabolite profiling, lipidomics and metagenomic sequencing, supported…
Serves biopharmaceutical companies, life sciences research teams, drug development groups, and microbiome or multiomics scientists involved in discovery, biomarker, pharmacokinetics, and biological…
Financial Health
StrongStrong · Hiring · 47% CAGR over 2y
Location
Sano Genetics Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops a software platform for precision medicine and clinical research that supports patient recruitment, genetic and biomarker testing, electronic medical record retrieval, digital consent, and…
Serves life sciences sponsors, CROs, clinical trial sites, and research initiatives running precision medicine studies, including pharma/biotech teams and patient advocacy or population genomics…
Financial Health
StrongStrong · Hiring · 57% CAGR over 4y
Location
Health Services Laboratories
Provides clinical pathology and diagnostic laboratory services for healthcare providers, including biochemistry, microbiology, haematology, genetics, immunology and virology testing, cervical…
Serves NHS trusts, hospitals, clinicians and other healthcare providers, as well as researchers and clinical trial teams requiring specialist laboratory support.
Location
Health Services Laboratories
Provides clinical pathology and diagnostic laboratory services including biochemistry, microbiology, genetics, immunology, haematology, virology and cervical screening. Processes medical samples and…
Serves NHS trusts and healthcare providers, including hospital clinicians and their patients, as well as research and clinical trial organisations requiring laboratory expertise.
Location
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops immunotherapy technologies aimed at improving how immune cells recognise and attack disease targets. Focuses on research into T‑cell interactions and technologies designed to enhance the…
Targets biopharmaceutical and cell therapy organisations developing CAR-T and other immunotherapies, alongside research collaborators and partners in immune-cell targeting.
Financial Health
DistressedDistressed · 0% CAGR over 1y
Location
Trajectory
3y · 2024–NowFinancial sub-scores
Computed from 3 filingsDevelops biotechnology for targeted gene delivery, using artificial intelligence to design and optimise systems that transport genetic material into specific cell types for research and potential…
Financial Health
WeakWeak · Hiring · 58% CAGR over 2y
Location
MY PERSONAL THERAPEUTICS LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops genomics‑based clinical decision support and drug screening services for cancer treatment. Uses tumour exome sequencing and fruit fly disease models to test approved and investigational…
Serves cancer patients and their families, particularly those with complex or hard-to-treat colorectal, lung, pancreatic and other GI cancers, as well as oncologists seeking personalized treatment…
Financial Health
StableStable · 2% CAGR over 4y
Location
NEXUS BIOQUEST LIMITED
Trajectory
2y · 2023–NowFinancial sub-scores
Computed from 2 filingsProvides contract research services in immunology for pharmaceutical and biotech drug discovery, including bespoke assay design, preclinical testing, target validation and mechanistic studies for…
Serves biotech and pharmaceutical R&D teams developing immune-focused therapeutics, including scientists working in immuno-oncology, autoimmunity, inflammation, hypersensitivity and neuroinflammation.
Financial Health
WeakWeak · Hiring · 179% CAGR over 1y
Location
MERIDIAN BIOSCIENCE INTERNATIONAL LIMITED
Trajectory
4y · 2020–NowFinancial sub-scores
Computed from 4 filingsDevelops and manufactures molecular and immunological reagents, diagnostic assays, and testing platforms for clinical diagnostics and life science research. Products include PCR master mixes,…
Sells primarily to healthcare laboratories, diagnostic providers, life science researchers and commercial assay developers needing molecular and immunological reagents, diagnostic tests and…
Financial Health
StableStable · -12% CAGR over 4y
Location
Relate Science Ltd
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops medicines using a data science and machine learning platform that analyses biomedical data to identify drug targets and opportunities. Uses a decentralized R&D model to collaborate with…
Financial Health
StrongStrong
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops pharmaceutical therapies for rare neurodegenerative diseases. Conducts research, clinical trials and drug development, including the IB1001 (N‑acetyl‑L‑leucine) programme, and works toward…
Serves patients with rare neurodegenerative diseases, their caregivers and families, and healthcare providers involved in treatment, clinical trials and expanded access.
Financial Health
StableStable · -16% CAGR over 4y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and commercialises biopharmaceutical medicines for rare diseases, with research and development focused on areas such as haematology and genetic disorders. Conducts clinical development,…
Serves healthcare professionals, hospitals and healthcare systems treating people with rare and debilitating diseases, including haematology, haemophilia and other rare-disease patient communities…
Financial Health
StrongStrong · Growing, Hiring · 16% CAGR over 4y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops immuno‑oncology therapies designed to enhance immune system response to cancer. Conducts research, drug development and clinical trials for therapeutic candidates, including CD47‑targeting…
Serves oncology patients and B2B healthcare stakeholders, including oncologists, clinical trial sites, healthcare organisations and biopharmaceutical partners involved in immuno-oncology.
Financial Health
StrongStrong
Location
Unlock all 721 leads
Showing 50 of 721 — +671 more with verified decision-maker contacts, live data, and CRM sync.
How London biotech companies work and how to sell to them
What they do
Most London biotech companies earn commercial income in uneven stages. Therapeutics developers often work towards upfront collaboration payments, milestone fees, licence income and later royalties, rather than repeatable product sales from day one. Diagnostics and discovery-tool suppliers are more likely to charge per assay, per sample, per study or through recurring access to a platform. Research-services groups sell scoped projects, validation work and specialist laboratory capacity. Many remain pre-revenue while equity funding, grants or partner funding pay for experiments, IP protection and regulatory preparation, so willingness to buy is often tied to the next scientific or financing milestone.
Who they sell to
Their buyers are usually technical and risk-aware: pharmaceutical R&D teams, translational medicine groups, diagnostic laboratories, academic-linked research teams, public-sector research bodies and investors reviewing life-sciences assets. A chief scientific officer, head of discovery or clinical operations lead typically sponsors the scientific case, while finance, procurement, legal and IP teams test cost, contracting risk and ownership. Sales cycles tend to run for months rather than weeks, especially where validation data, ethics review or clinical-readiness evidence is involved. Tools and services may move through direct scientific selling; public-sector work and larger collaborations more often involve tenders, partner processes or formal diligence.
What they buy
Most biotech firms tend to spend on laboratory consumables, wet-lab equipment, sample logistics, outsourced assay development, contract research, specialist recruitment and scientific consultancy. As programmes mature, buying shifts towards quality management, document control, regulatory affairs support, clinical operations, pharmacovigilance preparation, insurance, IP counsel and finance advice. Software demand is usually practical rather than speculative: electronic lab notebooks, laboratory information management, bioinformatics workflows, secure data rooms, cloud compute, cybersecurity, CRM for partnering pipelines, HR systems and procurement tools. Sellers should expect scrutiny on validation, audit trails, data security and whether a service fits existing laboratory and regulatory workflows.
Why and how to sell to them
Commercial intent is easiest to spot when a funding round closes, a senior scientific or clinical hire joins, a company prepares a clinical trial application, expands laboratory space, enters a partnership process or starts hiring regulatory and quality roles. Buyers tend to evaluate vendors when cash burn, experiment throughput, documentation quality or partner reporting becomes a constraint. Outbound works better when it is tied to a specific milestone: cleaner audit trails for MHRA-facing work, faster assay turnaround, better diligence packs, lower operational drag or fewer handoffs between lab, clinical and finance teams. Generic productivity claims usually underperform against evidence-led, risk-reduction messages.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in London
Related directories
Frequently asked questions
How many biotech companies are there in the London?↓
What counts as a biotech company in this list?↓
Which are the largest biotech companies in the London?↓
What do biotech companies in the London actually do?↓
How does London biotech compare internationally?↓
How is this list built and how fresh is the data?↓
How big are the typical biotech companies in the London?↓
Are these mostly new or established biotech companies?↓
What SIC codes does this use?↓
What buying signals should I look for?↓
Push these 721 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.